ADIL
- Adial Pharmaceuticals, Inc.
()
Overview
Company Summary
Adial Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of innovative medications to address alcohol use disorder (AUD), a chronic and devastating condition. They specifically aim to improve the treatment options available for individuals struggling with AUD.
ADIL is committed to developing therapeutic solutions for AUD using precision medicine, which involves tailoring treatments to an individual's unique genetic makeup. The company utilizes a proprietary genetic biomarker technology to identify individuals who have a specific genetic variant that may make them more likely to respond positively to ADIL's investigational drug, AD04.
AD04 is an orally administered therapeutic candidate under investigation for the treatment of AUD. It is a selective serotonin-3 antagonist, targeting the brain's serotonin receptors to potentially reduce the cravings and desire for alcohol.
Adial Pharmaceuticals' primary clinical program is centered around conducting clinical trials to assess the safety and efficacy of AD04. These trials aim to demonstrate the drug's ability to help patients reduce alcohol intake and improve clinical outcomes.
Besides their core focus on AUD, ADIL also explores potential applications of their technology and expertise in other psychiatric and addiction disorders, maximizing their value proposition and impact in the broader pharmaceutical industry.
In summary, Adial Pharmaceuticals, Inc. specializes in the development of precision medicine solutions for the treatment of alcohol use disorder, with their lead candidate drug AD04. Their objective is to provide safe and effective therapeutic options for individuals struggling with AUD, ultimately improving their quality of life.